Safe Harbor Vericel cautions you that all statements other than statements of historical fact included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting us and are subject to risks, assumptions, uncertainties and fact ...

Financial Performance - Total net revenue for Q1 2025 was $52.6 million, a 2.6% increase from $51.3 million in Q1 2024[7] - MACI net revenue reached $46.3 million, reflecting a 15% growth compared to the previous year[5] - Burn Care net revenue was $6.3 million, consisting of $5.0 million from Epicel and $1.3 million from NexoBrid[5] - Gross margin for Q1 2025 was 69%, consistent with the same period in 2024[8] - The net loss for Q1 2025 was $11.2 million, or $0.23 per diluted share, compared to a net loss of $3.9 million, or $0.08 per diluted share, in Q1 2024[12] - Non-GAAP adjusted EBITDA for Q1 2025 was $3.2 million, representing 6% of net revenue, down from $7.2 million, or 14% of net revenue, in Q1 2024[12] - Full-year total revenue guidance is reaffirmed with expected growth of 20% to 23%[10] - The company raised full-year profitability guidance to a gross margin of 74% and an adjusted EBITDA margin of 26%[10] - NexoBrid revenue increased by 207% year-over-year and 31% quarter-over-quarter[9] Asset and Liability Management - Total current assets decreased from $212,777 million in December 2024 to $197,640 million in March 2025, a decline of approximately 7.1%[26] - Cash and cash equivalents slightly decreased from $74,520 million to $73,490 million, a reduction of about 1.4%[26] - Total liabilities decreased from $140,755 million in December 2024 to $129,100 million in March 2025, a decrease of approximately 8.3%[26] - Total shareholders' equity increased from $291,967 million to $295,487 million, reflecting a growth of about 1.8%[26] - Accounts payable decreased significantly from $23,848 million to $16,751 million, a reduction of approximately 29.6%[26] - Accrued expenses decreased from $17,065 million to $11,418 million, a decline of about 33.3%[26] - Current liabilities decreased from $50,286 million to $39,448 million, a decrease of approximately 21.5%[26] - Long-term investments increased from $39,880 million to $43,342 million, reflecting an increase of about 8.7%[26] - Operating lease liabilities slightly decreased from $89,593 million to $87,804 million, a reduction of about 2.0%[26] - Total assets decreased from $432,722 million to $424,587 million, a decline of approximately 1.9%[26] Operational Highlights - The company trained approximately 400 MACI Arthro surgeons to date, with year-to-date biopsy growth exceeding 30% for trained surgeons[5]

Financial Performance - Total net revenue for Q1 2025 was $52.6 million, an increase from $51.3 million in Q1 2024 [5][21] - MACI net revenue grew by 15% to $46.3 million compared to the previous year [5][7] - Burn Care net revenue was $6.3 million, comprising $5.0 million from Epicel and $1.3 million from NexoBrid [5] - Gross margin remained stable at 69% [8] - The net loss for the quarter was $11.2 million, or $0.23 per diluted share, compared to a net loss of $3.9 million, or $0.08 per diluted share, in Q1 2024 [10][21] - Non-GAAP adjusted EBITDA for the quarter was $3.2 million, down from $7.2 million in Q1 2024 [10][22] Business Highlights - Approximately 400 MACI Arthro surgeons have been trained to date, with a year-to-date biopsy growth exceeding 30% for these trained surgeons [5][4] - The company reported the second highest number of MACI biopsies and surgeons taking biopsies since the product launch, with March recording the highest number of biopsies in any month since launch [5] - NexoBrid revenue increased by 207% year-over-year and 31% quarter-over-quarter [5] - Epicel saw the highest number of biopsies in a quarter since 2023 during Q1 2025 [5] Future Guidance - The company expects second quarter total revenue and MACI revenue growth to be in the low- to mid-20% range [5][6] - Full-year 2025 revenue guidance has been reaffirmed, with expected growth of 20% to 23% [6] - Profitability guidance has been raised to a gross margin of 74% and an adjusted EBITDA margin of 26% for the full year [6]

Company Overview - Vericel Corporation is a leader in advanced therapies for the sports medicine and severe burn care markets, combining innovations in biology with medical technologies to create a differentiated portfolio of cell therapies and specialty biologics [2] - The company markets three main products in the United States: MACI, Epicel, and holds an exclusive license for NexoBrid [2] Product Details - MACI is an autologous cellularized scaffold product for repairing symptomatic, full-thickness cartilage defects of the knee in adults [2] - Epicel is a permanent skin replacement for treating patients with deep dermal or full-thickness burns covering 30% or more of total body surface area [2] - NexoBrid is a biological orphan product indicated for eschar removal in patients with deep partial-thickness and/or full-thickness burns [2] Upcoming Events - Vericel Corporation will present at the Bank of America Securities 2025 Healthcare Conference on May 14, 2025, at 12:20 p.m. ET [1]

CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its first-quarter 2025 financial results on Thursday, May 8, 2025. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. Eric Burns ir@vcel.com +1 (734) 418-4411 About Vericel Corporation Vericel is a leading prov ...

Core Insights - Vericel (NASDAQ: VCEL) operates in the regenerative medicine sector, which is currently undervalued by the market [1] - The company has achieved steady revenue growth through FDA-approved products such as MACI, Epicel, and NexoBrid, contrasting with larger biotech firms focused on blockbuster drug approvals [1] Company Overview - Vericel has established a niche in regenerative medicine, differentiating itself from larger biotech companies [1] - The company’s revenue-generating products are recognized for their FDA approval, contributing to consistent revenue growth [1] Market Position - The market tends to overlook Vericel in favor of larger biotech names, despite its strong performance and growth potential [1] - The focus on high-growth companies in sectors with potential for exponential expansion aligns with Vericel's business model [1]

CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the following investor conferences: TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025Canaccord Genuity 2025 Musculoskeletal Conference on Monday, March 10, 2025Leerink Partners 2025 Global Healthcare Conference on Wednesday, March 12, 2025 A webcast of the presentatio ...

Vericel Corporation (NASDAQ:VCEL) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Nick Colangelo - CEO Joe Mara - CFO Eric Burns - VP, Finance and IR Conference Call Participants Ryan Zimmerman - BTIG Mike Kratky - Leerink Partners Felipe Lamar - Truist Securities Josh Jennings - TD Cowen Caitlin Cronin - Canaccord Genuity Mason Carrico - Stephens, Inc. Jeffrey Cohen - Ladenburg Thalmann & Co. Swayampakula Ramakanth - H.C. Wainwright & Co. Operator Good day, and thank you ...

Group 1 - Vericel Corporation held its Q4 2024 earnings conference call on February 27, 2025, at 8:30 AM ET [1][2] - The call featured key company executives including CEO Nick Colangelo and CFO Joe Mara [3] - The conference call was recorded and participants were initially in a listen-only mode [2][4] Group 2 - Forward-looking statements were made during the call, which are subject to risks and uncertainties that could lead to actual results differing from expectations [4] - The company provided access to its fourth quarter financial results press release and a presentation with highlights from the call on its Investor Relations website [4]

Vericel Corporation (VCEL) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.30 per share. This compares to earnings of $0.26 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 26.67%. A quarter ago, it was expected that this company would post a loss of $0.05 per share when it actually produced a loss of $0.02, delivering a surprise of 60%.Over the last four quarters, the company has ...